Objectives: To estimate the incremental cost per QALY in patients with Parkinson’s Disease (PD) with varying disease severity and to ascertain which patient subgroup would accrue the greatest net monetary benefits to Ontario’s public health perspective as a result of Deep Brain Stimulation (DBS).
Design: A cost-utility study and a net monetary benefit framework approach were applied to 37 PD patients with varying disease stages who underwent DBS treatment.
Results: DBS resulted in cost savings of $2,686.3, $2,752.4, and $7348.4 and QALY gains of 0.33, 0.09 and 0.04 in patients with mild, moderate and severe PD. The ICER was $16,076.2/QALY. At $50,000/QALY, the greatest net monetary benefits accrued to Ontario’s MOHLTC were from treating patients with mild PD with DBS.
Conclusions: DBS surgery was found to be a cost-effective PD treatment compared to pharmacotherapy. The greatest net monetary benefits were from treating patients with mild PD severity.